Plus Therapeutics (PSTV) Stock Price, News & Analysis

Company Overview

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America.

Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.

Key Stats

• Today's Range: $3.52 to $4.16
• 50-Day Range: $3.52 to $6.43
• 52-Week Range: $2.90 to $23.42
• Volume: 138,698 shs
• Average Volume: 116,506 shs
• Market Capitalization: $27.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.40
• Consensus Rating: Hold

Plus Therapeutics Stock Analysis - MarketRank™

Plus Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 687th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Plus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Plus Therapeutics has a consensus price target of $56.40, representing about 1,324.2% upside from its current price of $3.96.

Amount of Analyst Coverage

Plus Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Plus Therapeutics are expected to grow in the coming year, from ($3.76) to ($2.65) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Plus Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Plus Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Plus Therapeutics has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.57% of the float of Plus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Plus Therapeutics has a short interest ratio ("days to cover") of 4.21.

Change versus previous month

Short interest in Plus Therapeutics has recently decreased by 29.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Plus Therapeutics does not currently pay a dividend.

Dividend Growth

Plus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Plus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for PSTV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Plus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.50% of the stock of Plus Therapeutics is held by insiders.

Percentage Held by Institutions

3.28% of the stock of Plus Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 8/05/2026
• Next Earnings (Estimated): 8/13/2026
• 2026 SNO/ASCO CNS Metastases Conference: 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PSTV
• Previous Symbol: NASDAQ:CYTX
• CIK: 1095981
• Web: www.plustherapeutics.com
• Phone: 737-255-7194
• Fax: 858-450-4335
• Employees: 20
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Plus Therapeutics: $56.40
• High Price Target: $75.00
• Low Price Target: $25.00
• Potential Upside/Downside: +1,324.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.39 million
• Net Margins: -230.24%
• Pretax Margin: -230.24%
• Return on Equity: -198.48%
• Return on Assets: -73.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.27
• Quick Ratio: 2.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 5.50

Miscellaneous

• Outstanding Shares: 6,884,000
• Free Float: 6,712,000
• Market Cap: $27.26 million
• Optionable: Not Optionable
• Beta: 1.40